Perioperative effects of inhaled long acting beta2 adrenergic agonist/long acting muscarinic antagonist in patients with untreated COPD requiring surgery for lung cancer

Perioperative effects of inhaled long acting beta2 adrenergic agonist/long acting muscarinic antagonist in patients with untreated COPD requiring surgery for lung cancer - Perioperative effects of inhaled long acting beta2 adrenergic agonist/long acting muscarinic antagonist in untreated COPD patients with lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019358

Enrollment

Registered

2016-01-01

Start date

2017-03-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD requiring surgery for lung cancer

Interventions

Inhaled long acting beta2 adrenegic agonist/long acting muscarinic antagonist daily from the preoperative period (approximately 2 weeks before the operation) to 3 months after the operation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with newly diagnosed COPD during the cardio-pulmonary evaluation for lung surgery for lung cancer

Exclusion criteria

Exclusion criteria: Patients diagnosed with obstructive respiratory disorders other than COPD Patients with prior treatment for COPD Patients who cannot receive inhaled treatment because of its side-effect

Design outcomes

Primary

Measure	Time frame
The comparison of lung function (FVC,FEV1.0) between before and after two weeks of medication. The comparison of FEV1.0 and predicted FEV1.0 after three months of surgery.	—

Secondary

Measure	Time frame
COPD assesement (CAT) score at the beginning of inhalation, after two weeks, and after three months of surgery. Pulmonary complications in the postoperative period.	—

Countries

Japan

Contacts

Public ContactNobuyo Tamiya

Kyoto Prefectural University of Medicine Department of Respiratory medicine

koma@koto.kpu-m.ac.jp075-251-5513

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026